LYCA Lycia Therapeutics, Inc.
30.00USDMkt Cap: 1.56B $P/E: —Today
Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and al…
Industry Peers
Biotechnology$132.71BUSDP/E 30.5
$82.88BUSDP/E 19.9
$79.89BUSD
$66.19BUSD
$58.26BUSDP/E 24.1
$55.12BUSDP/E 31.5
$54.94BUSDP/E 30.3
$42.96BUSDP/E 67.6
$40.08BUSD
$36.90BUSDP/E 34.0
$29.98BUSDP/E 37.8
$26.93BUSDP/E 34.2
$26.36BUSD
$24.37BUSDP/E 32.6
$23.45BUSDP/E 14.7
$22.13BUSD
$20.39BUSD
$16.01BUSDP/E 18.3
$15.99BUSDP/E 20.4
$14.26BUSDP/E 36.7
Key Statistics
Company
Market Cap1.56B USD
Enterprise Value419.60M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)—
Revenue/Share—
Last Price30.00 USD
Fiscal Year End—
MR QuarterJun 2026
Employees31
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B—
EPS (TTM)—
EPS (Forward)—
52W Range
22.1955% of range36.49
52W High36.49 USD
52W Low22.19 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA—
ROIC—
ROCE—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF—
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-121.16M USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity2.18
Current Ratio—
Quick Ratio—
Book Value/Sh—
Cash/Share8.49 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.52.09M
Float—
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta—
S&P 52W Chg12.84%
Avg Vol (30d)2.27M
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—